丹参川芎嗪针治疗aPL阳性复发性流产的临床观察
Clinical Observation of Danshen Ligustrazine Injection in the Treatment of aPL Positive Recurrent Spontaneous Abortion
DOI: 10.12677/TCM.2019.82022, PDF,   
作者: 金三珊：湖北中医药大学，第一临床医学院，湖北 武汉；张迎春：湖北省妇幼保健院，中医科，湖北 武汉
关键词: 中药；丹参川芎嗪针；复发流产；低分子肝素；Traditional Chinese Medicine； Danshen Ligustrazine Injection； Recurrent Spontaneous Abortion； Low Molecular Weight Heparin
摘要: 目的：观察丹参川芎嗪针对aPL阳性复发性流产女性中的保胎疗效及安全性。方法：收集有效门诊病历180例；对照组与治疗组各90例，观察对照组(肝素 + 地屈孕酮 + 叶酸干预)与治疗组(在对照组基础上加用丹参川芎嗪针)患者血D二聚体(D-Di)、血小板聚集率及患者双侧子宫动脉RI、PI指标变化，并通过回访了解各组活产率、早产率及其它不良事件发生率。结果：治疗组总体活产率高于对照组(P < 0.05)。治疗组子痫前期、阴道出血发生率及药物性肝损伤发生概率低于对照组(P < 0.05)。两组早产率、胎儿畸形发生率无统计学意义(P > 0.05)。两组治疗后D-Di、血小板聚集率、双侧子宫动脉RI、PI值均呈下降趋势，且治疗组下降更明显(P < 0.05)。结论：丹参川芎嗪针能改善患者高血凝状态，改善患者妊娠期子宫血流动力学指标，促进妊娠的维持，增加活产率，降低子痫前期的发生。配合肝素使用，增强肝素抗凝及保胎作用，减轻肝素药物性肝损伤发生概率，不增加早产、胎儿畸形、阴道出血不良事件发生率。孕期用药安全性高。
Abstract: Objective: To observe the efficacy and safety of Danshen Ligustrazine Injection (DLI) in aPL-positive recurrent abortion women. Methods: 180 cases of selected outpatients were included in this experiment: 90 cases in the control group and 90 cases in the treatment group. Blood D-dimer (D-Di), platelet aggregation rate (PAR) and uterine artery RI and PI values of patients in the control group (heparin + dydrogesterone + folic acid) and the treatment group (DLI + heparin + dydrogesterone + folic acid) were detected. And the live birth rate, preterm birth rate and other adverse events were observed and calculated. Results: The overall live birth rate of the treatment group was higher than that of the control group (P < 0.05). The incidence of preeclampsia, vaginal bleeding and drug-induced liver injury in the treatment group was lower than that in the control group (P < 0.05). There was no significant difference in the incidence of premature birth rate and fetal malformation between the two groups (P > 0.05). D-Di, platelet aggregation rate, bilateral uterine artery RI, and PI values showed a downward trend after treatments in two groups, but the treatment group showed a more significant decrease (P < 0.05). Conclusion: DLI can improve the hypercoagulability of patients, improve the uterine hemodynamics during pregnancy, promote the maintenance of pregnancy, increase the live birth rate, and reduce the incidence of pre-pregnancy. In combination with heparin, it can enhance heparin anti-coagulation and anti-abortion effects, reduce the incidence of heparin drug-induced liver injury and does not increase the incidence of adverse events, such as premature delivery, fetal malformation and vaginal bleeding. The medication during pregnancy is safe and effective.
文章引用：金三珊, 张迎春. 丹参川芎嗪针治疗aPL阳性复发性流产的临床观察[J]. 中医学, 2019, 8(2): 120-127. https://doi.org/10.12677/TCM.2019.82022

参考文献

[1] D’Cruz, D.P. (2006) Antiphospholipid (Hughes) Syndrome: An Overview. In: Khamashta, M.A., Ed., Huges Syn-drome, Springer-Verlag, London, 9-21. [Google Scholar] [CrossRef] 
[2] Pattison, N.S., Chamley, L.W., McKay, E.J., Liggins, G.C. and Butler, W.S. (1993) Antiphospholipid Antibodies in Pregnancy: Prevalence and Clinical Associations. British Journal of Obstetrics and Gynaecology, 100, 909-913. [Google Scholar] [CrossRef] [PubMed]
[3] Birdsall, M., Pattison, N. and Chamley, L. (1992) Antiphospholipid Antibodies in Pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 32, 328-330. [Google Scholar] [CrossRef] 
[4] Lockwood, C.J., Romero, R., Feinberg, R.F., Clyne, L.P., Coster, B. and Hobbins, J.C. (1989) The Prevalence and Biologic Significance of Lupus Anticoagulant and Anticardiolipin Antibodies in a General Obstetric Population. American Journal of Obstetrics & Gynecology, 161, 369-373. [Google Scholar] [CrossRef] 
[5] Petri, M. (2006) Epidemiology of Antiphospholipid Antibody Syndrome. In: Khamashta, M.A., Ed., Huges Syndrome, Springer-Verlag, London, 22-28. [Google Scholar] [CrossRef] 
[6] Rai, R.S., Clifford, K., Cohen, H. and Regan, L. (2005) High Prospective Fetal Loss Rate in Untreated Pregnancies of Women with Recurrent Miscarriage and Antiphospholipid Antibodies. Human Reproduction, 10, 3301-3304. [Google Scholar] [CrossRef] [PubMed]
[7] Yasuda, M., Takakuwa, K., Tokunaga, A. and Tanaka, K. (1995) Prospective Studies of the Association between Anticardiolipin Antibody and Outcome of Pregnancy. Obstetrics & Gynecology, 86, 555-559. [Google Scholar] [CrossRef] 
[8] Allen, J.L., Tapia-Santiago, C. and Kutteh, W.H. (1996) Antiphospholipid Antibodies in Patients with Preeclampsia. American Journal of Reproductive Immunology, 36, 81-85. [Google Scholar] [CrossRef] [PubMed]
[9] Branch, D.W.M., Andres, R.M., Digre, K.B.M., Rote, N.S.P. and Scott, J.R.M. (1989) The Association of Antiphospholipid Antibodies with Severe Preeclampsia. Obstetrics & Gynecology, 73, 541-545.
[10] Katano, K., Aoki, K., Sasa, H., Ogasawara, M., Matsuura, E. and Yagami, Y. (1996) Beta 2-Glycoprotein I-Dependent Anticardiolipin Antibodies as a Predictor of Adverse Pregnancy Outcomes in Healthy Pregnant Women. Human Reproduction, 11, 509-512. [Google Scholar] [CrossRef] 
[11] Harris, E., Chan, J.H., Asherson, R.A., Aber, V.R., Gharavi, A.E. and Hughes, G.V. (1986) Thrombosis, Recurrent Fetal Loss, and Thrombocytopenia: Predictive Value of the Anticardiolipin Antibody Test. Archives of Internal Medicine, 146, 2153-2156. [Google Scholar] [CrossRef] [PubMed]
[12] Harris, E.N., Boey, M.L., Mackworth-Young, C.G., Gharavi, A.E., Patel, B.M., Loizou, S. and Hughes, G.R.V. (1983) Anticardiolipin Antibodies: Detection by Radioimmunoassay and Association with Thrombosis in Systemic Lupus Erythematosus. The Lancet, 322, 1211-1214. [Google Scholar] [CrossRef] 
[13] Reynaud, Q., Lega, J., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P. and Laporte, S. (2014) Risk of Venous and Arterial Thrombosis according to Type of Antiphospholipid Antibodies in Adults without Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 13, 595-608. [Google Scholar] [CrossRef] [PubMed]
[14] Wahl, D., Guillemin, F., de Maistre, E., Perret-Guillaume, C., Lecompte, T. and Thibaut, G. (1998) Meta-Analysis of the Risk of Venous Thrombosis in Individuals with Antiphospholipid Antibodies without Underlying Autoimmune Disease or Previous Thrombosis. Lupus, 7, 15-22. [Google Scholar] [CrossRef] [PubMed]
[15] Cabral, A.R., Cabiedes, J. and Alarcón-Segovia, D. (2004) Heterogeneity of Antibodies to Beta2-Glycoprotein 1 from Patients with Systemic Lupus Erythematosus. Lupus, 13, 182-187. [Google Scholar] [CrossRef] [PubMed]
[16] Jong, P.G.D., Quenby, S., Bloemenkamp, K.W., Braams-Lisman, B.A., de Bruin, J.P., Coomarasamy, A., David, M., DeSancho, M.T., van der Heijden, O.W., Hoek, A., Hutten, B.A., Jochmans, K., Koks, C.A., Kuchenbecker, W.K., Mol, B.W., Torrance, H.L., Scheepers, H.C., Stephenson, M.D., Verhoeve, H.R., Visser, J., de Vries, J.I., Goddijn, M. and Middeldorp, S. (2015) ALIFE2 Study: Low-Molecular-Weight Heparin for Women with Recurrent Miscarriage and Inherited Thrombophilia—Study Protocol for a Randomized Controlled Trial. Trials, 16, 208. [Google Scholar] [CrossRef] [PubMed]
[17] Check, J.H. (2012) The Use of Heparin for Preventing Miscarriage. American Journal of Reproductive Immunology, 67, 326-333. [Google Scholar] [CrossRef] [PubMed]
[18] Fouda, U.M., Sayed, A.M., Abdou, A.M., Ramadan, D.I., Fouda, I.M. and Zaki, M.M. (2010) Enoxaparin versus Unfractionated Heparin in the Management of Recurrent Abortion Secondary to Antiphospholipid Syndrome. International Journal of Gynecology & Obstetrics, 112, 211-215. [Google Scholar] [CrossRef] [PubMed]
[19] (2015) Correction to Dosage in: Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis: 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 148, 1529.
[20] Bouvier, S., Cochery-Nouvellon, E., GéraldineLavigne-Lissalde, G., Mercier, E., Marchetti, T., Balducchi, J.P., Marès, P. and Gris, J.C. (2013) Comparative Incidence of Pregnancy Outcomes in Treated Obstetric Antiphospholipid Syndrome: The NOH-APS Observational Study. Blood, 123, 404-413. [Google Scholar] [CrossRef] [PubMed]
[21] Bramham, K., Hunt, B.J., Germain, S., Calatayud, I., Khamashta, M., Bewley, S. and Nelson-Piercy, C. (2010) Pregnancy Outcome in Different Clinical Phenotypes of Antiphospholipid Syndrome. Lupus, 19, 58-64. [Google Scholar] [CrossRef] [PubMed]
[22] Zhao, Q.T., Guo, Q.M., Wang, P. and Wang, Q. (2012) Salvianic Acid a Inhibits Lipopolysaccharide-Induced Apoptosis through Regulating Glutathione Peroxidase Activity and Malondialdehyde Level in Vascular Endothelial Cells. Chinese Journal of Natural Medicines, 10, 53-57. [Google Scholar] [CrossRef] 
[23] 季亢挺, 唐疾飞, 陈鹏, 等. 丹参素保护内皮祖细胞炎症损伤的机制研究[J]. 中国预防医学杂志, 2010, 11(8): 809-812.
[24] Zhang, J.P., Zhang, Y.Y., Zhang, Y., Gao, Y.G., Ma, J.J., Wang, N., Wang, J.Y., Xie, Y., Zhang, F.H. and Chu, L. (2013) Salvia Miltiorrhiza (Danshen) Injection Ameliorates Iron Overload-Induced Cardiac Damage in Mice. Planta Medica, 79, 744-752. [Google Scholar] [CrossRef] [PubMed]
[25] 边金铎, 邓同乐, 许健, 等. 丹参素对H2O2诱导的内皮细胞氧化损伤的保护作用研究[J]. 上海中医药大学学报, 2012, 25(3): 61-65.
[26] 曹金仪. 丹参的化学成分及临床用途[J]. 中国医药指南, 2012, 10(29): 53-55.
[27] 裴艳霞. 川芎的药理作用及临床应用[J]. 中国医药指南, 2011, 9(34): 197-198.
[28] Wu, X.F., Zhang, F., Xiong, X., Lu, C., Lian, N., Lu, Y. and Zheng, S. (2015) Tetramethylpyrazine Reduces Inflammation in Liver Fibrosis and Inhibits Inflammatory Cytokine Expression in Hepatic Stellate Cells by Modulating NLRP3 Inflammasome Pathway. IUBMB Life, 67, 312-321. [Google Scholar] [CrossRef] [PubMed]
[29] 杨文辉, 龚国清, 周怡, 等. 川芎嗪体内抗血栓活性及机制探究[J]. 中国临床药理学与治疗学, 2012, 17(3): 241-245.
[30] Cai, X.X., Chen, Z., Pan, X.K., Xia, L., Chen, P., Yang, Y., Hu, H., Zhang, J., Li, K., Ge, J., Yu, K. and Zhuang, J. (2014) Inhibition of Angiogenesis, Fibrosis and Thrombosis by Tetramethylpyrazine: Mechanisms Contributing to the SDF-1/CXCR4 Axis. PLoS ONE, 9, e88176. [Google Scholar] [CrossRef] [PubMed]
[31] Xu, Q., Xia, P., Li, X., Wang, W., Liu, Z. and Gao, X. (2014) Tetramethylpyrazine Ameliorates High Glucose-Induced Endothelial Dysfunction by Increasing Mitochondrial Biogenesis. PLoS ONE, 9, e88243. [Google Scholar] [CrossRef] [PubMed]